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Abstract
Objective: To review the chemistry, pharmacology, microbiology, pharmacokinetics, pharmacodynamics, clinical efficacy, 
safety, dosage, and administration of bedaquiline, a novel oral diarylquinoline antimycobacterial agent approved by the 
Food and Drug Administration for the treatment of adults with pulmonary multidrug-resistant tuberculosis (MDR-TB). 
Data Sources: A search of PubMed (January 2004-May 2013) and International Pharmaceutical Abstracts (January 2004-
May 2013) using the search terms bedaquiline, diarylquinoline, R207910, and TMC207 was performed. Supplementary 
sources included proceedings of the Union World Conference on Lung Health. Study Selection and Data Extraction: 
Preclinical data as well as Phase 1 and 2 studies published in English were evaluated. Data Synthesis: Bedaquiline 
possesses a unique mechanism of action that disrupts the activity of the mycobacterial adenosine triphosphate synthase. 
Clinical trials have been conducted evaluating the use of bedaquiline in combination with a background regimen for 
the treatment of adults with pulmonary MDR-TB. Bedaquiline has an excellent in vitro activity against Mycobacterium 
tuberculosis, including multidrug resistant M tuberculosis; however, its side effect profile limits its use against MDR-TB when 
no other effective regimen can be provided. Bedaquiline carries Black Box warnings for increased risk of unexplained 
mortality and QT prolongation. Bedaquiline is metabolized via the CYP3A4 isoenzyme and thus interacts with rifamycins 
and several antiretrovirals. Conclusions: In an era of emerging resistance and given the suboptimal efficacy and toxicity of 
currently available regimens for MDR-TB, bedaquiline represents a great addition to the existing armamentarium of anti-TB 
agents particularly in areas of the world where the disease is endemic.
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Tuberculosis (TB) remains a major threat, killing millions 
of people every year around the world. According to the 
World Health Organization (WHO), in 2011, 8.7 million 
people were diagnosed with TB, and 1.4 million died from 
TB-related causes.1 Although the number of TB-infected 
patients is decreasing, the worldwide burden is still high 
and the WHO statistics related to the emergence of resis-
tant strains of mycobacteria are alarming.1 According to a 
WHO estimate, 3.7% of new TB patients has multidrug-
resistant TB (MDR-TB) defined as TB resistant to both 
isoniazid and rifampin.2 MDR-TB has emerged as a global 
public health issue, particularly in Brazil, Russia, India, 
China, and South Africa (BRICS), which account for 
approximately 60% of cases globally.2 Even more alarming 
are cases of extensively drug-resistant TB (XDR-TB), 
defined as TB resistant to isoniazid, rifampin, any fluoro-
quinolone, and any second-line injectable agent, which 
account for 9% of cases of MDR-TB.2 Whereas TB is usu-
ally responsive to a standard 2-month regimen of isoniazid, 
rifampin, pyrazinamide, and ethambutol, followed by a 
4-month regimen of isoniazid and rifampin, MDR and 
XDR-TB require more intensive and more prolonged regi-
mens, with second-line agents and up to 6 drugs, including 
injectables.3,4 These regimens are generally considered less 
effective, more toxic, and more expensive.5,6 Recently, a 
meta-analysis showed only a 44% success rate using sec-
ond-line agents in patients with XDR-TB with a mortality 
rate ranging between 14 and 27%.7 In the presence of HIV 
co-infection, the mortality rate exceeded 70%.8 Thus, the 
development of new agents that may shorten the duration 
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Bedaquiline fumarate
Chemical Formula: C36H35BrN2O6
Molecular Weight: 671.5769
Bedaquiline
Chemical Formula: C32H31BrN2O2
Molecular Weight: 555.50474
Figure 1. Chemical structures of bedaquiline fumarate and 
bedaquiline.
of therapy, improve adherence, decrease the risk of relapse, 
reduce mortality, and control the MDR-TB epidemic is 
warranted.3,9
This article provides a comprehensive clinical review on 
bedaquiline fumarate (Sirturo, Janssen Products, LP), a 
novel oral diarylquinoline antimycobacterial agent active 
against Mycobacterium tuberculosis, including MDR 
strains.10 It was formerly known as R207910 and TMC207 
and was originally developed through a partnership between 
Tibotec and the TB Alliance.11,12 On December 28, 2012, 
the FDA granted bedaquiline fast approval and an “orphan 
drug” designation to treat adults with MDR pulmonary TB 
as part of a combination therapy when an effective treat-
ment regimen cannot otherwise be provided.13 Bedaquiline 
was approved based on phase 2 data using time to sputum 
culture conversion as a surrogate marker for clinical effi-
cacy.13 Additional studies are currently being conducted to 
further evaluate its safety and efficacy in the treatment of 
MDR-TB.14
Data Sources
A search of PubMed (January 2004-May 2013) and 
International Pharmaceutical Abstracts (January 2004-May 
2013) using the search terms bedaquiline, diarylquinoline, 
R207910, and TMC207 was performed. All data available in 
English were reviewed. Supplementary sources included 
proceedings of the Union World Conference on Lung Health 
and information available from the manufacturer’s Web site.
Pharmacology and Chemistry
Bedaquiline belongs to a new class of antimycobacterial 
agents known as diarylquinolines.10 It exerts a bactericidal 
and sterilizing activity against M tuberculosis and selected 
nontuberculous mycobacteria by inhibiting the adenosine 
triphosphate (ATP) synthase.3 Bedaquiline targets the cen-
tral region of the c subunit of the enzyme, halting the energy 
production process and inhibiting the mycobacterium 
reproduction, resulting in its death.3,11,15 Unlike in many 
other bacteria, ATP synthase is essential for the optimal 
growth of M tuberculosis, and any mutation in the c subunit 
can lead to resistance to bedaquiline.10,11 The chemical 
name of bedaquiline (Figure 1) is (1R, 2S)-1-(6-bromo-2-
methoxy-3-quinol inyl ) -4-d imethylamino)-2- (1-
naphthalenyl)-1-phenyl-2-butanol.16 It is compounded with 
fumaric acid (1:1) as bedaquiline fumarate (Figure 1).17
Microbiology
Bedaquiline displays potent in vitro activity against both 
drug-susceptible and drug-resistant isolates of M tuberculo-
sis with minimum inhibitory concentrations (MICs) in the 
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range of 0.002 to 0.13 µg/mL (Table 1).18,19 It also exhibits 
bactericidal activity against dormant nonreplicating tuber-
cle bacilli.11 Bedaquiline displays potent in vitro activity 
against nontuberculous mycobacteria (Table 2).18,19 Three 
species of nontuberculous mycobacteria were found to be 
intrinsically resistant to bedaquiline: M novocastrense 
(MIC of 8.0 µg/mL), M shimoidei (MIC of 8.0 µg/mL), and 
M xenopi (MIC 4.0-8.0 µg/mL).19 Bedaquiline showed bac-
tericidal activity against M leprae in a murine leprosy 
model.20 Bedaquiline appears to have a narrow spectrum of 
activity targeted against Mycobacterium species because it 
displays weak activity against Gram-positive and Gram-
negative bacteria (Table 3).18
Resistance
The binding site of bedaquiline is in proximity to the 
amino acid residue Glu61 whose carboxyl group is proton-
ated during proton translocation of the ATP synthase. 
Mutations in positions 63 and 66 impede bedaquiline’s 
access to its target at residue 61, causing either intrinsic 
(as in M xenopi) or acquired (as in M tuberculosis) resis-
tance.21 The proportion of naturally occurring resistant 
mutants is low and estimated as 1 strain over 107/108 bac-
teria.18 M tuberculosis develops resistance to bedaquiline 
as a result of missense mutations of the atpE gene that 
disrupts the capacity of bedaquiline to bind to the c sub-
unit of the F0 domain of the ATP synthase. The mutation 
either occurs at position 63 with a proline substituting ala-
nine or at position 66 with a methionine substituting a leu-
cine.11,18,22 M segmatis develops resistance to bedaquiline 
as a result of a mutation at position 32 with valine substi-
tuting asparagine.18 Nontuberculous mycobacteria develop 
resistance to bedaquiline as a result of a mutation at posi-
tion 63 with methionine substituting alanine. Bedaquiline, 
as opposed to quinolones, does not seem to be subject to 
mutations within the DNA gyrase regions gyrA and gyrB.18
Table 1. In Vitro Activity of Bedaquilinea Against Mycobacterium 
tuberculosis.18,19
Organism Isolates, n Range of MICs (µg/mL)
M tuberculosis  
Drug susceptibleb,c 41 0.002-0.12
Multidrug resistantb,c 44 0.004-0.13
aSusceptibility to bedaquiline was determined using an agar dilution 
method.
bMIC
50
 = minimum inhibitory concentration for 50% of tested isolates  
= 0.03 µg/mL.
cMIC
90
 = minimum inhibitory concentration for 90% of tested isolates  
= 0.06 µg/mL.
Table 2. In Vitro Activity of Bedaquilinea Against 
Nontuberculous Mycobacterium Species.11,18,19
Organism Isolates, n Range of MICs (µg/mL)
Mycobacterium 
avium complexb
22 0.03-0.25
M abscessusc 1 NR
M chelonae 3 0.06-0.5
M conspicuum 1 0.13
M fortuitum 3 0.13-0.25
M gordonae 1 0.03
M hiberniae 1 0.03
M interjectum 1 0.03
M kansasii 1 0.03
M mageritense 1 0.03
M malmoense 1 0.5
M marinumd 1 NR
M phlei 2 0.03-0.13
M simiae 2 0.03
M smegmatis 7 0.003-0.01
M scrofulaceum 1 0.03
M szulgai 2 0.03-0.06
M terrae 2 0.03-0.13
M ulceranse 1 NR
M vaccae 2 0.03
Abbreviations: MIC
50
, minimum inhibitory concentration for 50% of 
tested isolates; NR, not reported; MIC
90
, minimum inhibitory concentra-
tion for 90% of tested isolates.
aSusceptibility to bedaquiline was determined using an agar dilution 
method.
bMIC
50
 = 0.03 µg/mL; MIC
90
 = 0.13 µg/mL.
cMedian MIC = 0.25 µg/mL.
dMedian MIC = 0.003 µg/mL.
eMedian MIC = 0.5 µg/mL.
Table 3. In Vitro Activity of Bedaquilinea Against Different 
Gram-Negative and -Positive Bacteria.18
Organism Isolates, n
Range of 
MIC
99
MIC
50
 
(µg/mL)
Corynebacterium jeikeium 1 4
C urealyticum 1 4
Helicobacter pylori 20 2 to >4 4
Nocardia asteroids 1 >16
N farcinia 1 >16
Escherichia coli 1 >32
Haemophilus influenza 1 >32
Streptococcus pneumoniae 10 16-64 >32
Staphylococcus aureus 1 >32
Abbreviations: MIC
50
 = minimum inhibitory concentration for 50% of 
tested isolates; MIC
99
 = minimum inhibitory concentration for 99% of 
tested isolates.
aSusceptibility to bedaquiline was determined using the standard CLSI 
(Clinical and Laboratory Standards Institute) method of susceptibility 
testing.
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Pharmacokinetics
Plasma pharmacokinetic parameters for bedaquiline admin-
istered orally are listed in Table 4. The maximum plasma 
concentrations (C
max
) and the area under the plasma concen-
tration–time curve (AUC) increased proportionally with 
increased doses of bedaquiline, which displays a linear phar-
macokinetic profile up to doses of 700 mg.18 The relative bio-
availability of bedaquiline increases by about 2-fold with the 
administration of a standard meal containing approximately 
22 g of fat as compared with administration on an empty 
stomach.10 Plasma concentrations were not affected by body 
weight, with data available only for patients with a body 
mass index of 14.1 to 26.9 kg/m2.23 The plasma protein bind-
ing of bedaquiline is higher than 99.9%. The volume of dis-
tribution in the central compartment is estimated to be 
approximately 164 L. In a murine model of TB, bedaquiline 
and its N-monodesmethyl metabolite (M2) were extensively 
distributed in the lungs, with AUC
168h
 lung/plasma ratios of 
about 20 for bedaquiline and 100 to 200 for its metabolite.24 
Bedaquiline is metabolized by CYP3A4 of the cytochrome 
P450 system and is primarily oxidized to its active M2, which 
has 4- to 6-fold lower antimycobacterial potency and lower 
average exposure (23% to 31%) than the parent drug.10,11,25 
Bedaquiline is primarily eliminated in the feces. Less than 
0.001% of the administered dose is eliminated unchanged in 
the urine. After reaching C
max
, bedaquiline concentrations 
decline triexponentially with time.18 This provides a rationale 
for less-frequent dosing regimens and for combining beda-
quiline with other drugs with long half-lives.25 The mean ter-
minal elimination half-life (t
1/2
) of bedaquiline and M2 is 
approximately 5.5 months and is independent of the adminis-
tered dose.11,18,26 This prolonged elimination likely reflects 
the slow release of bedaquiline and M2 from peripheral tis-
sues, which may accumulate and cause phospholipidosis.26
Pharmacodynamics
The exact pharmacokinetic-pharmacodynamic parameter 
that best correlates with bedaquiline has not been well 
elucidated. However, recent studies have shown that AUC 
is the primary activity driver of bedaquiline.24,27 In a study 
of early bactericidal activity (EBA) in treatment-naïve 
patients with smear-positive TB, oral bedaquiline at doses 
of 25, 100, and 400 mg had almost no bactericidal activity 
during days 2 to 4 of therapy.28 This may correlate with the 
interruption of cellular energy hemostasis. Bedaquiline 
showed bactericidal activity between days 4 to 7, with an 
overall decrease in mycobacterial colony counts of only 
0.77 log
10
 colony-forming units (CFU). These results are 
confirmed by a phase 2 study, where the decrease of myco-
bacterial CFU of bedaquiline 400 mg orally was 0.57 log
10
 
up to 7 days of therapy. The drug’s bactericidal activity was 
improved between weeks 1 and 4 suggesting a time-depen-
dent killing.23 In contrast, the EBA of bedaquiline appeared 
to increase with doses up to 400 mg daily and was estab-
lished following 2 loading doses and given for 14 days even 
at a low dose of 100 mg daily.27 Late bactericidal activity of 
bedaquiline against dormant or nonreplicating bacilli has 
the potential of shortening the duration of therapy.29 In a 
murine model of TB, bedaquiline demonstrated a greater 
bactericidal activity intracellularly in the peritoneal macro-
phage than on the extracellular bacilli because the prelimi-
nary static phase was shorter or absent.30 In another murine 
model, bedaquiline was shown to possess significant steril-
izing activity, and the substitution of bedaquiline for isonia-
zid or its addition to the standard anti-TB regimen allowed 
for reduction of the treatment duration to 4 months.31 
Bedaquiline displayed a synergistic effect with pyrazin-
amide-containing regimens in clearing bacterial counts in 
the lungs of mice after only 2 months of therapy.32 The 
14-day EBA of bedaquiline was also reported in treatment-
naïve patients with drug-susceptible uncomplicated TB.33 
M2 is not thought to contribute significantly to clinical effi-
cacy but appears to correlate with QT prolongation.10
Clinical Trials
Phase 2 Studies
The first study, TMC207-208, was designed in 2 stages: an 
exploratory stage followed by a proof-of-efficacy 
stage.23,26,27,34-36 The first stage consisted of a multicenter, 
placebo-controlled, double-blind, randomized trial that 
was conducted to assess safety and efficacy of bedaquiline 
in hospitalized adult patients with pulmonary MDR-TB in 
South Africa.23,26 Exclusion criteria included isolates not 
susceptible to aminoglycosides (other than streptomycin) 
and fluoroquinolones, previous treatment for MDR-TB, 
neurological or severe extrapulmonary manifestations of 
TB, HIV positive with a CD4+ count fewer than 300 cells/
µL, receipt of antiretrovirals or antifungals in the previous 
90 days, and significant cardiac arrhythmia. Patients were 
randomized into 2 groups. The first group consisted of 23 
Table 4. Bedaquiline Plasma Pharmacokinetics Parameters 
for Oral 25-, 100-, and 400-mg Daily Doses for 7 Days in 
Humans.10,28
Daily 
Dosea
C
max
  
(µg/mL) t
max
 (h)
AUC
0-24
  
(µg h/mL)
Effective 
t
1/2
 (hours)
25 mg 0.32 ± 0.09 3.93 (2.00-6.17) 3.97 ± 1.29 24
100 mg 1.21 ± 0.39 4 (1.97-8.00) 16.05 ± 5.07 24
400 mg 5.50 ± 2.96 4 (2.05-6.02) 64.75 ± 20.7 24
Abbreviations: C
max
, maximum concentration; t
max
, time to C
max
; AUC
0-24
, 
area under the concentration-time curve from 0 to 24 hours; t
1/2
, elimination 
half-life.
aAdministered as a daily oral dose for 7 days.
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patients who received bedaquiline 400 mg orally daily for 
2 weeks, followed by 200 mg 3 times a week for 6 weeks 
in combination with a standard 5-drug regimen for the 
treatment of MDR-TB. The second group consisted of 24 
patients who received placebo for 8 weeks in combination 
with a standard 5-drug regimen for the treatment of 
MDR-TB. The preferred standard regimen consisted of 5 
second-line agents: kanamycin, ofloxacin, ethionamide, 
pyrazinamide, and cycloserine or terizidone. Modifications 
to the background regimen were allowed according to cul-
ture and sensitivity results as well as tolerance to and 
availability of the medications. After completing 8 weeks 
of therapy with either bedaquiline or placebo, both groups 
continued to receive their background regimen and were 
followed up for a total of 2 years. It is important to note 
that the 8-week duration of therapy with bedaquiline in 
this trial was shorter than the 24-week duration of therapy 
approved by the FDA. The primary end point was the time 
to conversion of sputum cultures, in liquid broth, from 
positive to negative, which was defined as the interval 
between the date of treatment initiation and the date of the 
first of at least 2 consecutive negative weekly cultures. 
The secondary end point was the change from baseline in 
the log
10
 count of organism CFUs. The median age of 
patients was 33 years; 74% were male, 55% were black, 
13% were HIV positive, and 85% had cavitation in at least 
1 lung. At week 8, the time for conversion to a negative 
sputum culture was significantly reduced in the bedaqui-
line group compared with the placebo group using the Cox 
regression analysis: hazard ratio (HR) = 11.8; 95% CI = 
2.3 to 61.3; P = .003. At week 8, the rates of conversion to 
a negative culture were 48% in the bedaquiline group and 
9% in the placebo group, which results in a significant dif-
ference of 39%; 95% CI = 12.3 to 63.1; P = .004. The 
median log
10
 count also declined more rapidly in the beda-
quiline group than in the placebo group. During the 2-year 
follow-up, 23 patients discontinued throughout the course 
of the study: 10 from the bedaquiline group and 13 from 
the placebo group. Investigators cited noncompliance and 
the rigorous program of investigations for safety as rea-
sons for discontinuation from the study. At week 24, the 
time for conversion to a negative sputum culture remained 
significantly reduced in the bedaquiline group compared 
with the placebo group, using the Cox regression analysis: 
HR = 2.253; 95% CI = 1.08 to 4.71; P = .031. However, 
the rates of conversion to a negative culture were 81% in 
the bedaquiline group and 65.2% in the placebo group, 
which resulted in a nonstatistically significant difference 
of 15.8%; 95% CI = −11.9 to 41.9; P = .32. At week 104, 
the rate of treatment success was 52.4% in the bedaquiline 
group and 47.8% in the placebo group; the P value was not 
provided. It is important to note that during this trial, 1 
patient in the bedaquiline group (4.8%) acquired resis-
tance to companion drugs compared with 5 patients in the 
placebo group (21.7%); however, the difference did not 
reach statistical significance; P = .18.
The second stage of the study as reported in 2 webinars 
was similar in design to the first stage but included patients 
from Brazil, India, Latvia, Peru, Philippines, Russia, South 
Africa, and Thailand. Patients were randomized into 2 
groups.34,35 The first group consisted of 80 patients and 
received bedaquiline 400 mg orally once daily for the first 2 
weeks and 200 mg 3 times per week for the following 22 
weeks, in addition to a standard background regimen for the 
treatment of MDR-TB. The second group consisted of 81 
patients and received a placebo for 24 weeks in addition to 
a standard background regimen for the treatment of 
MDR-TB. The preferred background regimen was the same 
regimen used in the first stage of the study. Both groups 
continued to receive their background regimen for a total 
duration of 18 to 24 months. The primary efficacy end point 
was time to sputum culture conversion, in liquid broth, 
defined as 2 consecutive negative cultures collected at least 
25 days apart and not followed by a confirmed positive cul-
ture. The secondary efficacy end point was culture conver-
sion rate at week 24. The median age was 31 for the 
bedaquiline group and 35 for the placebo group; 66% were 
male in the bedaquiline group versus 61% in the placebo 
group; 9% were HIV positive in the bedaquiline group and 
18% in the placebo group. Efficacy analyses were based on 
the modified intention-to-treat population (mITT), which 
included 132 patients. The median time to sputum conver-
sion was 12 weeks in the bedaquiline group and 18 weeks in 
the placebo group; P = .003. At week 24, the sputum con-
version rate was 79% in the bedaquiline group and 58% in 
the placebo group; P = .008. The addition of bedaquiline to 
a background regimen for the treatment of MDR-TB 
resulted in a faster and a higher culture conversion rate. An 
analysis on all patients who completed 72 weeks of treat-
ment was conducted to compare the antibacterial and steril-
izing activities of the bedaquiline group compared with the 
placebo group and to compare culture conversion rates.35 
During the 72 weeks of follow-up, 57 patients discontinued 
throughout the course of the study—27 from the bedaqui-
line group and 30 from the placebo group. Investigators 
cited adverse events, withdrawal of consent, noncompli-
ance, and ineligibility or loss to follow-up as reasons for 
discontinuation from the study. Looking at the mITT popu-
lation, the median time to sputum conversion was 86 days 
for the bedaquiline group and 168 days for the placebo 
group; P = .029. Looking at all available data at week 88, 
the rates of conversion to a negative culture were 66.7% in 
the bedaquiline group and 47% in the placebo group, which 
resulted in a difference of 19.7%; P = .021.35
TMC207-209,36 the second phase 2 study, was a multi-
center phase 2 open-label study conducted to assess the 
safety and efficacy of bedaquiline in the treatment of adults 
with MDR-TB, including those with pre-XDR-TB and 
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XDR-TB from China, Estonia, Latvia, Peru, Philippines, 
Russia, South Korea, South Africa, Thailand, Turkey, and 
Ukraine. Pre-XDR-TB was defined as resistance to either a 
fluoroquinolone or a second-line injectable drug. Exclusion 
criteria included severe extrapulmonary manifestations of 
TB, HIV positive with a CD4+ count fewer than 250 cells/
µL, and receipt of certain antiretrovirals. Patients received 
bedaquiline 400 mg orally daily for 14 days, followed by 
200 mg 3 times a week for 22 weeks in addition to an opti-
mized background regimen that included fluoroquinolones, 
ethionamide/protionamide, pyrazinamide, aminoglyco-
sides, cycloserine/terizodone, and ethambutol. Patients con-
tinued to receive the background regimen for 18 to 24 
months, and modifications to the background regimen were 
allowed. The primary end point was the time to sputum cul-
ture conversion in liquid broth. Efficacy analyses were 
based on the mITT, which included 205 patients. The 
median age was 32 years; 64% were male; 5% were HIV 
positive; 54% had MDR-TB; 25% had pre-XDR-TB; and 
21% had XDR-TB. The median time to culture conversion 
was 8 weeks, and the conversion rate at week 24 was 79.5%. 
In the subset of patients with MDR-TB, the median time to 
culture conversion was 8 weeks, and the conversion rate at 
week 24 was 87.1%. In the subset of patients with pre-
XDR-TB, the median time to culture conversion was 12 
weeks, and the conversion rate at week 24 was 77.3%. 
Finally, in the subset of patients with XDR-TB, the median 
time to culture conversion was 24 weeks, and the conver-
sion rate at week 24 was 55.6%.
Phase 3 Studies
A phase 3 placebo-controlled, double-blind, randomized 
trial of 600 adults with smear-positive MDR or pre-XDR-
TB is being planned to provide safety and efficacy data for 
bedaquiline; however, the study is not yet open for partici-
pant recruitment.14 The first arm is scheduled to receive 
bedaquiline 400 mg daily for the first 2 weeks and 200 mg 
3 times a week for 22 weeks in combination with a back-
ground regimen for the treatment of MDR-TB. The second 
arm is scheduled to receive placebo in combination with the 
same background regimen for the treatment of MDR-TB. 
Patients will be followed for 84 weeks, and the primary end 
point is the number of patients with favorable outcome at 
week 60.14,35 Another phase 3 study is currently being con-
ducted to evaluate early access of bedaquiline to adults with 
smear-positive pre-XDR or XDR-TB.14
Safety, Warnings, and Precautions
Bedaquiline was studied as part of a combination regimen 
for the treatment of MDR-TB.26,27,34-36 As a consequence, 
most of the side effects observed during clinical trials are 
known to occur in patients receiving second-line agents for 
the treatment of MDR-TB: anorexia, arthralgia, chest pain, 
headache, hemoptysis, increase in amylase, increase in 
transaminases, nausea, and rash.10 There are no contraindi-
cations to the use of the drug.10 However, bedaquiline was 
associated with an increased risk of unexplained mortality 
(boxed warning), restricting its use to when no other regi-
men can be provided.10 Bedaquiline was also associated 
with an increased risk of QT prolongation (boxed warning) 
requiring ECG monitoring before initiation of treatment 
and at least at 2, 12, and 24 weeks after starting treatment 
and requiring drug discontinuation in the presence of clini-
cally significant ventricular arrhythmia or when QTcF (QT 
interval corrected using Fridericia’s formula) exceeds 500 
ms.10 Bedaquiline was also associated with hepatic-related 
adverse events, requiring drug discontinuation in the pres-
ence of significant or persistent increase in aminotransfer-
ases.10 Specifically, increases in transaminases and blood 
amylase were reported more frequently in the bedaquiline 
group (8.9% and 2.5%, respectively) than in the placebo 
group (1.2% and 1.2%, respectively).10
Safety data from the first stage of TMC207-208 revealed 
that the most common adverse events associated with the 
bedaquiline group were nausea (26.1%), extremity pain 
(17.4%), bilateral hearing impairment (13.0%), acne (8.7%), 
and chest pain (4.3%).27 Nausea and increases in the mean 
QTcF were the only adverse events that occurred signifi-
cantly more frequently in the bedaquiline arm than in the 
placebo arm.27 Safety data from the second stage of 
TMC207-208 revealed that the most common adverse events 
associated with the bedaquiline group were nausea (34%), 
arthralgia (34%), headache (27%), hyperuricemia (25%), 
vomiting (25%), hemoptysis (19%), pruritus (13%), insom-
nia (13%), dizziness (11%), abdominal pain (11%), back 
pain (10%), and pyrexia (10%).34 Adverse events, including 
nausea and increases in the mean QTcF, were evenly distrib-
uted across treatment groups.34 However, a secondary analy-
sis of TMC207-208 revealed 10 deaths in the bedaquiline 
arm compared with 2 deaths in the placebo arm, and the dif-
ference was statistically significant.37 The exact cause of this 
difference in mortality is unknown. Finally, safety data from 
TMC207-209 revealed that the most common adverse events 
associated with the bedaquiline group were hyperuricemia 
(14%), arthralgia (12%), and nausea (11%).36
Drug Interactions
Because bedaquiline is metabolized by CYP3A4, its blood 
concentration and therapeutic effect may be altered by 
coadministration with CYP3A4 inducers or inhibitors. 
Coadministration of bedaquiline 300 mg daily and rifampin 
600 mg daily for 21 days to healthy individuals resulted in 
significant reduction of AUC to bedaquiline (52%), render-
ing the drug potentially ineffective; therefore, clinicians 
should avoid combining bedaquiline with strong CYP3A4 
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inducers, such as rifampin, rifabutin, and rifapentine.10 
Coadministration of bedaquiline 400 mg daily for 14 days 
and ketoconazole 400 mg daily for 4 days to healthy indi-
viduals resulted in an increase of AUC to bedaquiline 
(22%), rendering the drug potentially toxic; therefore, clini-
cians should avoid combining bedaquiline with strong 
CYP3A4 inhibitors for more than 14 consecutive days 
unless the benefit outweighs the risk.10
Coadministration of bedaquiline 400 mg daily for 14 
days and isoniazid 300 mg daily plus pyrazinamide 1000 
mg daily for 5 days to healthy individuals did not result in 
significant changes of AUC to bedaquiline, isoniazid, or 
pyrazinamide; therefore, dosage adjustment is not neces-
sary when combining bedaquiline with isoniazid and pyra-
zinamide.10 During clinical trials, the administration of 
bedaquiline with ethambutol, kanamycin, pyrazinamide, 
ofloxacin, and cycloserine to patients with MDR-TB did 
not result in any significant drug-drug interactions.10 
Therefore, and with the exception of rifamycins, bedaqui-
line can be safely administered with other TB agents with-
out dosage adjustment.
Coadministration of bedaquiline 400 mg, single dose, 
and lopinavir 400 mg plus ritonavir 100 mg twice daily 
for 24 days to healthy individuals resulted in increase of 
AUC to bedaquiline (22%), rendering the drug potentially 
toxic; therefore, clinicians should use bedaquiline with 
lopinavir plus ritonavir only if the benefits outweigh the 
risks.10 Coadministration of bedaquiline 400 mg single 
dose and nevirapine 200 mg twice daily for 28 days to 
patients with HIV did not result in significant changes of 
AUC to bedaquiline; therefore, bedaquiline can be safely 
administered with nevirapine without dosage adjust-
ment.10 Coadministration of bedaquiline 400 mg, single 
dose, on day 1 and another 400 mg, single dose, on day 29 
and efavirenz 600 mg daily from day 15 to 28 to healthy 
individuals did not result in significant pharmacokinetic 
interactions, suggesting that the effect of efavirenz on 
single-dose bedaquiline is unlikely to be clinically sig-
nificant.38 However, coadministration of bedaquiline 400 
mg, single dose, on day 1 and another 400 mg, single 
dose, on day 43 and efavirenz 600 mg daily from day 15 
to 42 to healthy individuals provided a model where 
investigators predicted a 52% reduction in the average 
steady-state concentrations of bedaquiline with chronic 
administration and proposed one of the following adjust-
ments to the bedaquiline regimen: 400 mg daily for 2 
weeks followed by 200 mg daily for 22 weeks or 400 mg 
daily for 2 weeks followed by 400 mg 3 times weekly for 
22 weeks.39
Finally, coadministration of bedaquiline with ketocon-
azole resulted in a synergistic effect on QTc interval prolon-
gation.10 Coadministration of bedaquiline with clofazimine 
also resulted in an increased QTc interval.10 This may increase 
the risk of arrhythmias, including torsades de pointes.
Availability, Dosage, and 
Administration
Bedaquiline is supplied as 100-mg tablets.10 The recom-
mended dose for the current FDA-approved indication of 
MDR-TB as part of combination therapy in adults (≥18 
years) is 400 mg administered orally once daily for the first 2 
weeks and 200 mg 3 times per week thereafter for a total of 
24 weeks.10 Bedaquiline should be administered with food by 
directly observed therapy.10 An FDA-approved medication 
guide should be dispensed with this medication.10
Special Populations
The safety and efficacy of bedaquiline are not yet estab-
lished in the pediatric and geriatric populations.10 Although 
bedaquiline is classified as pregnancy category B, it should 
be used during pregnancy only if clearly indicated because 
human data are not available.10 It is not known whether 
bedaquiline is excreted in breast milk; therefore, its use in 
nursing mothers involves weighing the benefits of the drug 
to the mother and the risk of adverse reactions to the infant.10 
No dosage adjustment is necessary in patients with mild to 
moderate hepatic or renal impairment.10 Bedaquiline should 
be used with caution in patients with severe hepatic or renal 
impairment and in patients undergoing dialysis because it 
has not been well studied in this population.10
Formulary Considerations
Because cases of MDR-TB are currently rare in the United 
States where only 98 cases occurred in 2011, the use of beda-
quiline is likely to be limited at least for the near future; how-
ever, the proportion of new cases of MDR-TB has increased 
from 0.9% in 2008 to 1.3% in 2011.40 In other parts of the 
world, TB and specifically MDR-TB are more prevalent, par-
ticularly in the BRICS countries.2 As of October 2012 and 
according to the WHO, 84 countries reported at least 1 case of 
XDR-TB.2 Hence bedaquiline represents an important addi-
tion to the armamentarium of agents against TB in these coun-
tries. Evidence from phase 2 studies showed faster sputum 
conversion rates with bedaquiline than placebo. This may 
shorten the duration of treatment, improve adherence, achieve 
higher cure rates, and preserve the activity of the background 
regimen.41 However, concerns regarding increased mortality 
restrict bedaquiline use to cases where no alternative options 
are possible. QT prolongation also limits bedaquiline use in 
patients with cardiac conduction abnormalities and in patients 
receiving other QT-prolonging agents, such as macrolides, 
fluoroquinolones, and azole antifungals. CYP3A4 interac-
tions warrant patient monitoring, particularly when bedaqui-
line is concomitantly prescribed with rifamycins and/or 
antiretrovirals. Finally, the cost of a 24-week course of ther-
apy with bedaquiline is $36 000.00 (average wholesale price), 
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which is higher than the cost of other second-line agents com-
monly used in the treatment of MDR-TB.42
Conclusions
Bedaquiline, a first-in-class diarylquinoline, was shown to be 
effective in combination with other agents for the treatment of 
adults with pulmonary MDR-TB. It is the first anti-TB agent 
to be approved by the FDA in more than 40 years. The novelty 
of the drug is in its unique mechanism of action, wherein it 
inhibits the proton pump activity of ATP synthase in M tuber-
culosis. Bedaquiline has shown promising results in phase 2 
clinical studies; however, it has been associated with several 
adverse events, including nausea, arthralgia, headache, 
hemoptysis, and chest pain. In addition, bedaquiline has 2 
boxed warnings for increased mortality and QT prolongation 
and a warning regarding hepatic-related adverse reactions. 
Also, it has serious drug interactions with CYP3A4 inducers 
and inhibitors and other QT-prolonging agents. Phase 3 stud-
ies are definitely needed to further evaluate its safety, efficacy, 
and tolerability in patients with TB. If proven safe and effec-
tive, bedaquiline will be particularly useful in areas of the 
world where MDR-TB is prevalent but with careful monitor-
ing for adverse effects and drug interactions, although its cost 
may represent a burden in resource-limited countries.
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